These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 1382903)

  • 21. Autologous and allogeneic mixed-lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2, and a prostaglandin inhibitor, WY-18251.
    Antonacci AC; Calvano SE; Reaves LE; Prajapati A; Bockman R; Welte K; Mertelsmann R; Gupta S; Good RA; Shires GT
    Clin Immunol Immunopathol; 1984 Feb; 30(2):304-20. PubMed ID: 6229378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-2 responsiveness of lectin-induced lymphoblasts: soluble IL-2 receptor release and differential in vitro effects of immunosuppressants.
    Hornung N; Raskova J; Raska K; Degiannis D
    Int J Immunopharmacol; 1992 Jul; 14(5):753-60. PubMed ID: 1512072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of regulation of T-cell responses by soluble inhibitory factors from the sera of patients with Hodgkin's disease.
    Damle RN; Advani SH; Gangal SG
    Int J Cancer; 1992 Jan; 50(2):192-6. PubMed ID: 1730512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies.
    Mantovani G; Macciò A; Lai P; Ghiani M; Turnu E; Del Giacco GS
    Cell Biophys; 1995 Aug; 27(1):1-14. PubMed ID: 7493395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
    Simsek H; Kadayifci A
    J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapamycin inhibits the in vitro release of soluble interleukin-2 receptor by activated peripheral blood mononuclear cells (PBMC) independently of the mode of activation.
    Degiannis D; Hornung N
    Int J Immunopharmacol; 1995 Jul; 17(7):593-6. PubMed ID: 8586487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells.
    Zorn U; Dallmann I; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Cytokine; 1994 Jul; 6(4):358-64. PubMed ID: 7948742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of hCG and beta-hCG on IL-2 and sIL-2R secretion from human peripheral blood mononuclear cells: a dose-response study in vitro.
    Komorowski J; Gradowski G; Stepień H
    Immunol Lett; 1997 Oct; 59(1):29-33. PubMed ID: 9334854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
    Srivastava MD; Srivastava A; Srivastava BI
    Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble forms of p55-IL-2R alpha, CD8, and CD30 molecules as markers of lymphoid cell activation in infectious mononucleosis.
    Vinante F; Morosato L; Siviero F; Nadali G; Rigo A; Veneri D; de Sabata D; Vincenzi C; Chilosi M; Semenzato G
    Haematologica; 1994; 79(5):413-9. PubMed ID: 7843627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of human syncytiotrophoblast plasma membrane vesicles on Jurkat cells activated by phorbol ester and calcium ionophore.
    Thibault G; Degenne D; Lacord M; Guillaumin JM; Girard AC; Bardos P
    Cell Immunol; 1992 Jan; 139(1):259-67. PubMed ID: 1309491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with solid tumors.
    Orditura M; De Vita F; Roscigno A; Auriemma A; Infusino S; Catalano G
    Int J Mol Med; 1998 Jul; 2(1):75-9. PubMed ID: 9854147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin 2 receptor expression by T cells in human aging.
    Orson FM; Saadeh CK; Lewis DE; Nelson DL
    Cell Immunol; 1989 Dec; 124(2):278-91. PubMed ID: 2510938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-2 receptor expression and function following thermal injury.
    O'Riordain DS; Mendez MV; Holzheimer RG; Collins K; Mannick JA; Rodrick ML
    Arch Surg; 1995 Feb; 130(2):165-70. PubMed ID: 7848087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of IL-2R alpha-chain is enhanced by activation of adenylate cyclase in large granular lymphocytes and natural killer cells.
    Koyasu S; Tagaya Y; Sugie K; Yonehara S; Yodoi J; Yahara I
    J Immunol; 1991 Jan; 146(1):233-8. PubMed ID: 1845805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2.
    Gooding R; Riches P; Dadian G; Moore J; Gore M
    Br J Cancer; 1995 Aug; 72(2):452-5. PubMed ID: 7640231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility.
    Peter JB; Boctor FN; Tourtellotte WW
    Neurology; 1991 Jan; 41(1):121-3. PubMed ID: 1985276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble and cellular markers of immune activation in patients with systemic sclerosis.
    Degiannis D; Seibold JR; Czarnecki M; Raskova J; Raska K
    Clin Immunol Immunopathol; 1990 Aug; 56(2):259-70. PubMed ID: 2116249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
    Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
    Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.